Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y Guideline. is
resource is a practice tool based on ASCO
®
practice guidelines and is not intended to substitute for the independent
professional judgment of the treating physician. Practice guidelines do not account for individual variation among
patients. is pocket guide does not purport to suggest any particular course of medical treatment. Use of the practice
guidelines and this resource are voluntary. e practice guidelines and additional information are available at
www.asco.org/g ynecologic-cancer-guidelines. Copyright ©2020 by American Society of Clinical Oncolog y.
All rights reserved.
Source
Konstantinopoulos P, Norquist B, Lacchetti C, et al: Germline and somatic tumor testing in epithelial ovarian
cancer: ASCO Guideline. J Clin Oncol doi: 10.1200/JCO.19.02960
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2020 All rights reserved
ASCOGER2012
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical tools
and resources, is available at www.asco.org/g ynecologic-cancer-guidelines.
Abbreviations
dMMR, mismatch repair deficiency; FDA, Food and Drug Administration; HRD, homologous recombination
deficiency; VUS, variant of uncertain significance
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-
based
B Benefits outweigh
harms
H High Strong
CB
Consensus-
based
H Harms outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative balance of
benefits and harms
L Low Weak
U Benefits/harms ratio
uncertain
Ins Insufficient